Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer The MANTA Phase 2 Randomized Clinical Trial

Schmid, P; Zaiss, M; Harper-Wynne, C; Ferreira, M; Dubey, S; Chan, S; Makris, A; Nemsadze, G; Brunt, AM; Kuemmel, S; Ruiz, I; Perello, A; Kendall, A; Brown, J; Kristeleit, H; Conibear, J; Saura, C; Grenier, J; Mahr, K; Schenker, M; Sohn, J; Lee, KS;

Schmid, P (reprint author), Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, Old Anat Bldg,Charterhouse Sq, London EC1M 6BQ, England.

JAMA ONCOLOGY, 2019; 5 (11): 1556

Abstract

IMPORTANCE Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mamma......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索